Pilot study to investigate differences in middle molecules, oxidative stress and markers of peripheral vascular disease in patients treated by high flux haemodialysis and haemodiafiltration.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
05
2021
accepted:
21
09
2021
entrez:
6
10
2021
pubmed:
7
10
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Dialysis patients have an increased risk of mortality. Recently treatment with haemodiafiltration (HDF) has been reported to reduce mortality, particularly cardiovascular mortality, compared to standard high-flux haemodialysis (HD). However, why HDF may offer a survival advantage remains to be determined. So, we conducted a pilot study to explore differences in middle-molecules, inflammation and markers of vascular disease in patients treated by HD and HDF. Observational cross-sectional study measuring serum β2-microglobulin (β2M), Advanced Glycosylation End Products (AGEs) by skin autofluorescence (SAF), oxidative stress with ischaemia modified albumin ratio (IMAR) and peripheral vascular disease assessment using Ankle-Brachial Index (ABI), and arterial stiffness using Cardio-Ankle Vascular Index (CAVI). We studied 196 patients, mean age 69.1 ± 12.4 years, 172 (87.8%) treated by HD and 24 (12.2%) by HDF. Age, body mass index, co-morbidity and dialysis vintage were not different between HD and HDF groups. Middle molecules; β2M (31±9.9 vs 31.2±10 ug/mL) and SAF (2.99±0.72 vs 3.0±0.84 AU), ABI (1.06±0.05 vs 1.07±0.10) and CAVI (9.34±1.55 vs 9.35±1.23) were not different, but IMAR was higher in the HD patients (38.4±14.8 vs 31.3 ± 17.4, P = 0.035). In this pilot observational study, we found patients treated by HDF had lower oxidative stress as measured by IMAR, with no differences in middle molecules. Lower oxidative stress would be expected to have diverse protective effects on the cardiovascular system Although we found no differences in ABI and CAVI, future studies are required to determine whether reduced oxidative stress translates into clinically relevant differences over time.
Sections du résumé
BACKGROUND
Dialysis patients have an increased risk of mortality. Recently treatment with haemodiafiltration (HDF) has been reported to reduce mortality, particularly cardiovascular mortality, compared to standard high-flux haemodialysis (HD). However, why HDF may offer a survival advantage remains to be determined. So, we conducted a pilot study to explore differences in middle-molecules, inflammation and markers of vascular disease in patients treated by HD and HDF.
METHODS
Observational cross-sectional study measuring serum β2-microglobulin (β2M), Advanced Glycosylation End Products (AGEs) by skin autofluorescence (SAF), oxidative stress with ischaemia modified albumin ratio (IMAR) and peripheral vascular disease assessment using Ankle-Brachial Index (ABI), and arterial stiffness using Cardio-Ankle Vascular Index (CAVI).
RESULTS
We studied 196 patients, mean age 69.1 ± 12.4 years, 172 (87.8%) treated by HD and 24 (12.2%) by HDF. Age, body mass index, co-morbidity and dialysis vintage were not different between HD and HDF groups. Middle molecules; β2M (31±9.9 vs 31.2±10 ug/mL) and SAF (2.99±0.72 vs 3.0±0.84 AU), ABI (1.06±0.05 vs 1.07±0.10) and CAVI (9.34±1.55 vs 9.35±1.23) were not different, but IMAR was higher in the HD patients (38.4±14.8 vs 31.3 ± 17.4, P = 0.035).
CONCLUSIONS
In this pilot observational study, we found patients treated by HDF had lower oxidative stress as measured by IMAR, with no differences in middle molecules. Lower oxidative stress would be expected to have diverse protective effects on the cardiovascular system Although we found no differences in ABI and CAVI, future studies are required to determine whether reduced oxidative stress translates into clinically relevant differences over time.
Identifiants
pubmed: 34614018
doi: 10.1371/journal.pone.0258223
pii: PONE-D-21-14692
pmc: PMC8494338
doi:
Substances chimiques
Biomarkers
0
ischemia-modified albumin
0
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0258223Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nephrol Dial Transplant. 2017 Mar 1;32(3):548-555
pubmed: 28025382
Br J Nutr. 2015 Apr 14;113(7):1040-3
pubmed: 25761438
J Atheroscler Thromb. 2006 Apr;13(2):101-7
pubmed: 16733298
J Am Coll Cardiol. 2006 Sep 19;48(6):1190-7
pubmed: 16979004
Nephrol Dial Transplant. 2016 Jul;31(7):1145-51
pubmed: 26682964
Hypertens Res. 2011 Jun;34(6):779-83
pubmed: 21471974
Clin Biochem. 2012 Apr;45(6):450-4
pubmed: 22342921
Circulation. 2006 Oct 31;114(18):1914-22
pubmed: 17060384
Diabetologia. 2004 Jul;47(7):1324-1330
pubmed: 15243705
J Am Soc Nephrol. 2013 Feb;24(3):487-97
pubmed: 23411788
Hemodial Int. 2014 Apr;18(2):391-5
pubmed: 24299472
J Cell Mol Med. 2017 May;21(5):1024-1032
pubmed: 27957792
J Ren Nutr. 2019 Mar;29(2):149-155
pubmed: 30309781
Artif Organs. 2018 Nov;42(11):1078-1085
pubmed: 29611208
PLoS One. 2018 Jun 18;13(6):e0198320
pubmed: 29912924
Hypertension. 2018 Jun;71(6):1126-1132
pubmed: 29712739
Vasc Med. 2018 Oct;23(5):419-425
pubmed: 29985113
Kidney Int. 2003 Jun;63(6):2207-13
pubmed: 12753309
Nephrology (Carlton). 2015 Nov;20(11):862-7
pubmed: 26014842
J Atheroscler Thromb. 2011;18(11):924-38
pubmed: 21628839
Int J Hypertens. 2019 Feb 17;2019:9189362
pubmed: 30906591
Kidney Int. 2007 Aug;72(3):247-59
pubmed: 17568785
J Atheroscler Thromb. 2008 Dec;15(6):339-44
pubmed: 19060424
J Am Soc Nephrol. 2005 Dec;16(12):3687-93
pubmed: 16280473
Ann N Y Acad Sci. 2005 Jun;1043:290-8
pubmed: 16037251
Hepatology. 2009 Aug;50(2):555-64
pubmed: 19642174
Am J Nephrol. 2008;28(6):949-57
pubmed: 18594136
Kidney Int. 2016 Jan;89(1):193-9
pubmed: 26352299
Blood Purif. 2019;47 Suppl 2:19-24
pubmed: 30943515
J Epidemiol Community Health. 1988 Jun;42(2):128-33
pubmed: 3065437